Effect of Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome
Launched by ZENG CHANGHAO · Feb 22, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective Virtual Reality Therapy can be in helping patients with Wallenberg Syndrome who have difficulty swallowing, a condition known as dysphagia. Participants in the trial will receive traditional treatment for dysphagia along with Virtual Reality Therapy once a day for two weeks. Researchers want to find out if using virtual reality can improve swallowing abilities more than just the conventional treatment alone.
To be eligible for the trial, participants must be between 18 and 85 years old, right-handed, and have difficulty swallowing confirmed by a specific swallowing test. They should be stable and conscious, without significant cognitive impairment, and have no previous issues with swallowing from other conditions like Parkinson's disease. Throughout the study, participants can expect to engage in both standard therapy and virtual reality exercises designed to improve their swallowing skills. The trial is currently recruiting, so if you or someone you know fits the criteria, it could be a great opportunity to help advance treatment for this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ranged from 18-85 years and right-handed;
- • first onset, vital signs stable and conscious;
- • the dysphagia confirmed by videofluoroscopic swallowing study;
- • no cognitive impairment, the mini-mental state examination score: \>17 for those with an illiterate education, \>20 for those with an elementary education, and \>24 for those with a secondary education and above;
- • cranial integrity without craniotomy and/or craniectomy;
- • patient and/or his/her relative agrees and signs written informed consent.
- Exclusion Criteria:
- • combined ischemic foci at other sites;
- • presence of organic swallowing dysfunction or pre-existing dysphagia due to Parkinson's disease, dementia, and others;
- • severe cardiac, pulmonary, hepatic, and renal insufficiency and vital organ failure;
- • infected or broken skin on the head;
- • poorly controlled epilepsy;
- • poor patient compliance.
About Zeng Changhao
Zeng Changhao is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethically conducted clinical studies. With a commitment to improving patient outcomes, Zeng Changhao collaborates with leading healthcare professionals and research institutions to explore novel therapies and treatment modalities. The organization emphasizes transparency, compliance, and patient safety, ensuring that all trials adhere to the highest regulatory standards. Through its strategic partnerships and a patient-centric approach, Zeng Changhao aims to contribute significantly to the development of effective and safe healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Xinzhu, , Taiwan
Patients applied
Trial Officials
Nieto Luis, Master
Study Director
Site Coordinator of United Medical Group located in Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported